1-3 of 3
Ryan A. Wilcox
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma

Clinical Trials & Observations
Tycel J. Phillips, David Bond, Radihka Takiar, Karson Kump, Malalthi Kandarpa, Philip Boonstra, Tera Lynn Mayer, Victoria Nachar, Ryan A. Wilcox, Shannon A. Carty, Yasmin H. Karimi, Zaneta Nikolovska-Coleska, Mark S. Kaminski, Alex F. Herrera, Kami Maddocks, Leslie Popplewell, Alexey V. Danilov
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4518–4527.
https://doi.org/10.1182/bloodadvances.2023009992
Published: 2023
Includes: Supplemental data
Journal Articles

Postibrutinib relapse outcomes for patients with marginal zone lymphoma

Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Xiao-wei Cherie Tan, Kathryn Lindsey, Joseph Maakaron, Paolo F. Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Timothy S. Oh, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A. David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P. Kenkre, Adam J. Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T. Awan, Juan Pablo Alderuccio, Stefan K. Barta, Natalie S. Grover, Nilanjan Ghosh, Nancy L. Bartlett, Alex F. Herrera, Geoffrey Shouse
Journal: Blood Advances
Blood Adv (2023) 7 (1): 88–91.
https://doi.org/10.1182/bloodadvances.2022008634
Published: 2023
Includes: Supplemental data
Journal Articles

The role of aurora A and polo-like kinases in high-risk lymphomas

Clinical Trials & Observations
Carlos Murga-Zamalloa, Kedar V. Inamdar, Ryan A. Wilcox
Journal: Blood Advances
Blood Adv (2019) 3 (11): 1778–1787.
https://doi.org/10.1182/bloodadvances.2019000232
Published: 2019